Correlation between Genetic Polymorphism of CYP2A13 Genotype and Lung Cancer in Female Passive Smokers
Abstract
Background: Nicotine is metabolized to cotinine by cytochrome P450 enzyme, and this enzyme is involved in the activation of toxic and carcinogenic substances. The aim of this research was to assess the relationship between genetic polymorphism of CYP2A13 and lung cancer incidence in female passive smokers.
Materials and methods: This research was a case-control study that involved 104 research subjects. Subjects were recruited through purposive sampling technique from 2 hospitals in Medan, North Sumatra, Indonesia. The case population consisted of female passive smokers with lung cancer and the control population consisted of female passive smokers without lung cancer. All research subjects underwent blood sampling for genomics DNA extraction and CYP2A13 genotyping by polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP). Data was analyzed by conditional logistic regression by Epi Info 7.0 software.
Results: Among 104 subjects, 26 (25%) individuals were heterozygous, 76 (73%) individuals were wild type, and 2 (2%) were mutant for the 257Cys allele. There was a significant correlation between CYP2A13 genotype and lung cancer incidence (p-value<0.05). Female passive smokers with CT genotype had 2.7 greater risk of developing lung cancer than those with CC genotype (wild type). The C allele had more frequency and 1.6 times higher risk of lung cancer compared to T allele with a wide confidence range (0.73–3.52).
Conclusion: There was a significant correlation between CYP2A13 polymorphism and lung cancer incidence in female passive smokers.
Keywords: polymorphism, CYP2A13, PCR-RFLP, female passive smoker, lung cancer
Full Text:
PDFReferences
Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011; 61(2): 69–90, CrossRef.
Cufari ME, Proli C, De Sousa P, Raubenheimer H, Al Sahaf M, Chavan H, et al. Increasing frequency of non-smoking lung cancer: Presentation of patients with early disease to a tertiary institution in the UK. Eur J Cancer. 2017; 84: 55–9, CrossRef.
Subramanian J, Govindan R. Lung cancer in never smokers: A review. J Clin Oncol. 2007; 25(5): 561-70, CrossRef.
Soeroso NN, Ananda FR. Lung cancer among never-smoker women: An epidemiological data in North Sumatera, Indonesia. Int J Respir Med. 2019; 1(1): 1-9, article.
Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA Cancer J Clin. 2020; 70(1): 7-30, CrossRef.
Dela Cruz CS, Tanoue LT, Matthay RA. Lung cancer: Epidemiology, etiology, and prevention. Clin Chest Med. 2011; 32(4): 605-44, CrossRef.
Nordquist LT, Simon GR, Cantor A, Alberts WM, Bepler G. Improved survival in never-smokers vs current smokers with primary adenocarcinoma of the lung. Chest. 2004; 126(2): 347–51, CrossRef.
Subramanian J, Velcheti V, Gao F, Govindan R. Presentation and stage-specific outcomes of lifelong never-smokers with non-small cell lung cancer (NSCLC). J Thorac Oncol. 2007; 2(9): 827–30, CrossRef.
Toh CK, Gao F, Lim WT, Leong SS, Fong KW, Yap SP, et al. Never-smokers with lung cancer: Epidemiologic evidence of a distinct disease entity. J Clin Oncol. 2006; 24(15): 2245–51, CrossRef.
Clément-Duchêne C, Vignaud JM, Stoufflet A, Bertrand O, Gislard A, Thiberville L, et al. Characteristics of never smoker lung cancer including environmental and occupational risk factors. Lung Cancer. 2010; 67(2): 144-50, CrossRef.
Harris JE. Cigarette smoke somponents and disease: Cigarette smoke is more than a triad of tar, nicotine and carbon monoxide. In: Shopland DR, editor. The FTC Cigarette Test Method for Determining Tar, Nicotine, and Carbon Monoxide Yields of US Cigarettes: Report of the NCI Expert Committee. Bethesda: National Cancer Institute; 1994. p.59-75, article.
Pass HI, Carbone DP, Johnson D, Minna JD, Scagliotti GV, Turrisi A. Principles and Practice of Lung Cancer: The Official Reference Text of the International Association for the Study of Lung Cancer (IASLC). 4th ed. Philadelphia: Lippincott Williams & Wilkins; 2010, article.
Hecht SS. Tobacco smoke carcinogens and lung cancer. J Natl Cancer Inst. 1999; 91(14): 1194–210, CrossRef.
Zhang X, Su T, Zhang QY, Gu J, Caggana M, Li H, et al. Genetic polymorphisms of the human CYP2A13 gene: Identification of single-nucleotide polymorphisms and functional characterization of an Arg257Cys variant. J Pharmacol Exp Ther. 2002; 302(2): 416-23, CrossRef.
Cheng XY, Chen GL, Zhang WX, Zhou G, Wang D, Zhou HH. Arg257Cys polymorphism of CYP2A13 in a Chinese population. Clin Chim Acta. 2004; 343(1-2): 213-6, CrossRef.
Su T, Bao Z, Zhang QY, Smith TJ, Hong JY, Ding X. Human cytochrome P450 CYP2A13: Predominant expression in the respiratory tract and its high efficiency metabolic activation of a tobacco-specific carcinogen, 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone. Cancer Res. 2000; 60(18): 5074-9, article.
Zhang X, D'Agostino J, Wu H, Zhang QY, von Weymarn L, Murphy SE, et al. CYP2A13: Variable expression and role in human lung microsomal metabolic activation of the tobacco-specific carcinogen 4-(Methylnitrosamino)-1-(3-pyridyl)-1-butanone. J Pharmacol Exp Ther. 2007; 323(2): 570-8, CrossRef.
Bao Z, He XY, Ding X, Prabhu S, Hong JY. Metabolism of nicotine and cotinine by human cytochrome P450 2A13. Drug Metab Dispos. 2005; 33(2): 258-61, CrossRef.
Şahinoğulları ZU. Cytochrome P450 2A13 3375C>T gene polymorphism in a Turkish population. Istanbul J Pharm. 2020; 50(3): 181–7, CrossRef.
Alberg AJ, Brock MV, Samet JM. Epidemiology of lung cancer: Looking to the future. J Clin Oncol. 2005; 23(14): 3175-85, CrossRef.
Hakkola J, Hukkanen J, Turpeinen M, Pelkonen O. Inhibition and induction of CYP enzymes in humans: An update. Arch Toxicol. 2020; 94(11): 3671–722, CrossRef.
Bhopal A, Peake MD, Gilligan D, Cosford P. Lung cancer in never-smokers: A hidden disease. J R Soc Med. 2019; 112(7): 269–71, CrossRef.
Soeroso NN, Sinaga BYM, Zain-Hamid R, Sadewa AH, Syahruddin E. The CYP2A13 Arg257Cys polymorphism and its relationship to lung cancer. In: Adella CA, editor. Stem Cell Oncology: Proceedings of the International Stem Cell and Oncology Conference (ISCOC, 2017) 2017 Dec 1-2, Medan. London: CRC Press; 2018. p.265-9, CrossRef.
Timofeeva MN, Kropp S, Sauter W, Beckmann L, Rosenberger A, Illig T, et al. CYP450 polymorphisms as risk factors for early-onset lung cancer: Gender-specific differences. Carcinogenesis. 2009; 30(7): 1161-9, CrossRef.
Wang H, Tan W, Hao B, Miao X, Zhou G, He F, et al. Substantial reduction in risk of lung adenocarcinoma associated with genetic polymorphism in CYP2A13, the most active cytochrome p450 for the metabolic activation of tobacco-spesific carcinogen NNK. Cancer Res. 2003; 63(22): 8057-61, article.
Mong C, Garon EB, Fuller C, Mahtabifard A, Mirocha J, Mosenifar Z, et al. High prevalence of lung cancer in a surgical cohort of lung cancer patients a decade after smoking cessation. J Cardiothorac Surg. 2011; 6: 19, CrossRef.
Saragih HM. Profil penderita kanker paru yang dirawat di Rindu A3 (RA3) RSUP Haji Adam Malik Medan Tahun 2007-2010 [Thesis]. Medan: Universitas Sumatera Utara; 2012, article.
Kumar V, Abbas A, Aster J. Buku Ajar Patologi Dasar Robbins. 10th ed. Singapore: Elsevier (Singapore) Pte Ltd; 2019.
Marleen FS, Syahruddin E, Hudoyo A, Endarjo S. Ekspresi protein Bcl-2 pada sediaan blok parafin jaringan kanker paru. J Respir Indones. 2009; 29(4): 1-13, article.
Malik PS, Sharma MC, Mohanti BK, Shukla NK, Deo S, Mohan A, et al. Clinico-pathological profile of lung cancer at AIIMS: A changing paradigm in India. Asian Pac J Cancer Prev. 2013; 14(1): 489-94, CrossRef.
Torres-Duque C, Maldonado D, Pérez-Padilla R, Ezzati M, Viegi G. Biomass fuels and respiratory diseases: A review of the evidence. Proc Am Thorac Soc. 2008; 5(5): 577–90, CrossRef.
Lim WY, Seow A. Biomass fuels and lung cancer. Respirology. 2012; 17(1): 20–31, CrossRef.
DOI: https://doi.org/10.21705/mcbs.v6i2.246
Copyright (c) 2022 Cell and BioPharmaceutical Institute
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Indexed by:
Cell and BioPharmaceutical Institute
